Method of treating raynaud's disease secondary to connectivitis using aminaphtone
The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration.
1. A method for treating arteriopathies, wherein said arteriopathies is Raynaud's disease secondary to connectivitis, the method comprising the step of administering, to a subject in need thereof, a pharmaceutical composition comprising aminaphtone.
2. The method according to claim 1 , wherein said pharmaceutical composition is administered by enteral or parenteral administration.
3. The method according to claim 2 , wherein said pharmaceutical composition is administered via the oral route.
4. The method according to claim 1 , wherein said pharmaceutical composition contains a quantity of active ingredient aminaphtone in a quantity between 30 and 150 mg/dose.
5. The method according to claim 3 , wherein said pharmaceutical composition further includes a quantity of excipients selected from: carriers, buffering agents, lubricants, dispersants, flavourings, sweeteners, stabilizers, preservatives, antioxidants commonly used in the pharmaceutical formulation technique.
6. The method according to claim 1 , wherein said pharmaceutical composition is administered in daily dose of between 30 and 350 mg/day.
7. The method according to claim 6 , wherein said pharmaceutical composition is administered in daily dose of between 50 and 300 mg/day.
8. The method according to claim 7 , wherein said pharmaceutical composition is administered in daily dose of between 75 and 250 mg/day.